DIMOCO Notifies German Mobile Network Operators Telefónica Germany, Telekom and Vodafone as Payment Agents
1.10.2020 14:05:00 EEST | Business Wire | Press release
Since January 2018, mobile network operators (MNOs) are obliged to operate under the telecommunication exemption of PSD2 regulation, entitling them to only process digital goods, ticketing, parking and charities, but restricts them to extend the billing of goods and services outside the telecommunication exemption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005598/en/
DIMOCO Presse Release: DIMOCO notifies German Mobile Network Operators Telefónica Germany, Telekom and Vodafone as Payment Agents (Graphic: Business Wire)
The DIMOCO agent model enables MNOs to operate under the company’s financial license, enabling them to process payments for goods and services outside this exemption.
DIMOCO, a leading provider for direct MNO connections in Europe, currently obtains 210 MNO connections in 48 countries, covering 90 percent of Europe. Since 2016, DIMOCO operates under its payment license, granted by the Austrian Financial Market Authority (FMA) and passported into all EU member states. Consequently, DIMOCO can process transactions for goods and services outside the telecommunication exemption of PSD2 under its licence for MNOs who have been notified as DIMOCO agents.
"Obtaining an own license has been a route that most of the MNOs haven’t pursued as it's a very complex and costly procedure. Being notified as a DIMOCO agent is not only much faster and easier, MNOs can also benefit from our expertise and experience as a licensed payment institute," explains Clemens Leitner, Executive Vice President, Carrier & Business Development at DIMOCO Carrier Billing. "We are all set to deploy DCB payments for carsharing, taxis, rental of e-scooters, electric car charging and many other industries, emphasizing on a solid legal basis."
The German MNOs Telefónica Germany, Telekom and Vodafone have been the first to recognize the immense potential of the agent model partnership with DIMOCO and the vast market possibilities under this model. Out of a German population of currently 83.02 million inhabitants only 40 million people own a credit card and 23 million hold a PayPal account. In 2019, over 140 million mobile subscriptions were registered in Germany, ranking carrier billing as the payment method with the highest penetration and subsequently widest reach, available to more potential customers than any other payment method.
About DIMOCO
DIMOCO Carrier Billing is a European-wide regulated payment institute for Direct Carrier Billing and holds a payment service license from the Austrian Financial Market Authority (FMA), passported to all EU member states.
As a trusted partner of mobile network operators, it enables over one billion subscribers to purchase goods and services from merchants and aggregators with their mobile devices, charged via the operators’ billing system.
Website: dimoco.eu/carrierbilling
Twitter: @Dimoco
LinkedIn: @DIMOCO Carrier Billing
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005598/en/
Contact information
More information
Picture material
High resolution
Low resolution
@DIMOCO
Press contact
DIMOCO Corporate Headquarters
Charlotte Newby
+43 1 33 66 888 – 2059
c.newby@dimoco.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
